Advancements in the management of immune checkpoint inhibitors for urothelial carcinoma among geriatric patients
Urothelial cell carcinoma(UCC)is a malignant tumor originating from the epithelium of the urinary tract organs.Surgery is one of the main treatment methods for UCC,but the current treatment effect remains poor.Immunotherapy,as a new type of treatment emerging in recent years,aims to block tumor proteins or immune cell receptors that bind to tumor proteins,thus activating the immune cells to work by killing cancer cells.The choice of therapeutic regimen for elderly UCC patients is often complicated by their pathological and physiological characteristics,but due to the special characteristics of the elderly population,there is a lack of large-scale randomized controlled trials on immune checkpoint inhibitors for the treatment of elderly patients.This article reviews the use of immunosuppressants in elderly patients with reference to clinical trials that included elderly UCC patients.
NETL
NSTL
万方数据
